# After Lyme Neuroborreliosis Treatment: How Common Are Lingering Symptoms? A Patient's Guide to a Major Scientific Review

Lyme neuroborreliosis is a tick-borne infection of the nervous system, and many patients wonder whether symptoms will permanently disappear after antibiotic treatment. This systematic review of 44 clinical studies involving 1,469 patients found that approximately 28% of patients experience some residual symptoms after treatment, but the actual rate depends heavily on how strictly the original diagnosis was confirmed. When researchers used the more rigorous "probable/definite" case definition requiring laboratory confirmation, the rate dropped to 24%, whereas studies using the broader, less specific "possible" definition reported 31% — and symptoms like the often-feared debilitating fatigue appeared only in the less rigorous studies. These findings suggest that reports of a dramatic "post-Lyme syndrome" with chronic fatigue may be partly an artifact of including patients who never truly had Lyme neuroborreliosis.

# After Lyme Neuroborreliosis Treatment: How Common Are Lingering Symptoms? A Patient's Guide to a Major Scientific Review

## Table of Contents

- Key Points
- Background: What Is Lyme Neuroborreliosis?
- Why This Research Matters to Patients
- Study Methods: How the Research Was Conducted
- Key Findings: Overall Rate of Residual Symptoms
- The Case Definition Effect: 24% vs. 31%
- How Study Design Affected the Numbers
- The Spectrum of Symptoms: What Patients Actually Reported
- The "Post-Lyme Syndrome" Controversy
- Clinical Implications: What This Means for Patients
- Limitations: What This Study Could Not Prove
- Recommendations for Patients
- Frequently Asked Questions
- Source Information

## Key Points

- About 28% of 1,469 Lyme neuroborreliosis patients had residual symptoms; with confirmed diagnosis, the rate was 24%.
- Common lingering symptoms include pain, cranial neuropathy, and cognitive disturbances; most were mild in studies that assessed severity.
- Fatigue was never reported in rigorous diagnostic studies, suggesting it points to other conditions rather than post-Lyme syndrome.
- Standard antibiotic treatment lasts 14–21 days; prolonged antibiotics for 'chronic Lyme' are not supported by evidence.
- Roughly 72–76% of patients with confirmed Lyme neuroborreliosis recover completely after standard treatment.

## Background: What Is Lyme Neuroborreliosis?

Lyme neuroborreliosis (LNB) is an infectious disease of the nervous system caused by the spiral-shaped bacterium *Borrelia burgdorferi* sensu lato, which is transmitted through tick bites. The disease is common in the temperate, wooded regions of the Northern Hemisphere, with an incidence of approximately **111 cases per 100,000 people per year**.

The infection affects the nervous system in **3–15% of all Lyme disease patients**. When it does, it typically causes polyradiculoneuritis (inflammation of nerve roots, often with pain or weakness) and may or may not involve the cranial nerves (the nerves that control facial muscles, vision, and other head functions). Meningitis (inflammation of the membranes surrounding the brain and spinal cord) is also common.

More serious central nervous system involvement can occur, especially in prolonged cases, including encephalomyelitis (inflammation of both the brain and spinal cord) and Borrelia-induced vasculitis (inflammation of blood vessels in the brain) that can lead to stroke-like ischemic lesions. Lyme disease can also affect other organ systems, causing skin problems, arthritis, or, rarely, Lyme carditis (inflammation of the heart).

Interestingly, the bacterial subspecies responsible matters too. In Europe, the genospecies *Borrelia garinii* appears to affect the nervous system more often than other types such as *Borrelia burgdorferi* sensu stricto or *Borrelia afzelii*. The diagnosis of LNB is usually based on clinical symptoms, blood tests (serologic testing), and analysis of cerebrospinal fluid (CSF) obtained through a lumbar puncture.

Standard treatment follows guidelines from the European Federation of Neurological Sciences and the Infectious Diseases Society of America. Patients receive antibiotic therapy with beta-lactam drugs — ceftriaxone, penicillin, or cefotaxime — or doxycycline, generally for **14–21 days**.

## Why This Research Matters to Patients

Even after this antibiotic treatment, some patients continue to experience symptoms. This has generated considerable controversy. Some researchers and patient advocacy groups have suggested that a large proportion of patients develop a "post-treatment Lyme disease syndrome" marked by debilitating fatigue and cognitive impairment, and some have even argued that patients suffer from chronic infection requiring extended antibiotic courses.

This uncertainty creates real anxiety. Patients who continue to feel unwell may distrust their doctors or fear they will never recover. The researchers behind this study wanted to provide clear answers to a practical question: **How common are residual symptoms after properly treated Lyme neuroborreliosis, and what kind of symptoms are they?**

It is worth noting that clinicians do not routinely discuss prolonging or repeating antibiotic treatment for well-recognized residual symptoms (pain, cognitive impairment, fatigue) after other nervous system infections, such as viral encephalitis or post-herpetic radiculopathy. This observation raises a key question: why would Lyme disease be different?

Some experts argue that the symptoms attributed to "post-Lyme syndrome" are actually non-specific and exist as "background symptoms" in the general population — a view supported by case-control studies comparing Lyme patients to healthy controls. Others doubt the syndrome exists at all, suggesting that the patients described may actually be suffering from other conditions, such as fibromyalgia, that simply do not respond to antibiotics. Knowing the true prevalence and pattern of residual symptoms helps doctors counsel patients realistically about what to expect, provides mental support to those who do have lingering issues, and helps flag unusual symptom patterns that might suggest a different diagnosis.

## Study Methods: How the Research Was Conducted

This was a systematic review — a type of study that gathers all available scientific evidence on a question using rigorous, pre-defined methods. The research team, based at the University of Freiburg in Germany, searched three major medical databases (Medline, EMBASE, and CENTRAL) and three clinical trial registries to find every eligible study reporting on pharmacological (drug) treatment of Lyme neuroborreliosis in adults.

The investigators set clear eligibility rules. Studies had to have diagnosed LNB according to consensus-derived case definitions. Small case series with fewer than five participants were excluded. There were no restrictions on study design or language — meaning they looked at everything from randomized controlled trials to simple case reports, in any language.

The initial search identified **5,779 bibliographic records** after removing duplicates. Of these, 5,660 were excluded based on titles and abstracts, and 118 full-text articles were examined in detail. In the end, **44 studies met the eligibility criteria**.

The included studies broke down as follows:

-
**8 randomized controlled trials (RCTs)** — the gold standard of medical evidence
-
**17 cohort studies** — studies that follow a group of patients over time
-
**2 case-control studies** — studies comparing affected patients to unaffected controls
-
**17 case series** — descriptive reports of groups of patients

Data on the prevalence (how common residual symptoms were) came from 38 of these studies, while 31 provided detailed information on the spectrum (which specific symptoms occurred). Follow-up periods ranged widely across the studies, from as short as **7 days to as long as 20 years**.

The researchers pooled the data using a random-effects model, a statistical technique appropriate when studies are expected to differ from one another. They also performed sensitivity analyses using a fixed-effect model to test the robustness of their findings, investigated heterogeneity (statistical variability between studies) using the I² test, and used funnel plots to look for publication bias.

Importantly, they divided the studies into two groups based on which case definition was used to diagnose LNB:

-
**"Probable/definite" definition** — rigorous criteria that typically require laboratory confirmation, including cerebrospinal fluid analysis showing specific antibody production
-
**"Possible" definition** — a broader, less specific definition that may not require laboratory confirmation

Of the 44 studies, 13 used the stricter "probable/definite" definition, while 31 used the "possible" definition. They compared symptom rates between these two groups using Pearson's chi-squared test with Yates' continuity correction, and applied the conservative Bonferroni correction to guard against false positives when making multiple comparisons.

## Key Findings: Overall Rate of Residual Symptoms

The headline result is straightforward. Across all 34 studies that reported prevalence data, the mean weighted proportion of patients experiencing **any residual symptom at the last reported follow-up was 28%** (95% confidence interval [CI] 23–34%). In plainer terms, this means that roughly **one in four patients** had some lingering symptom after treatment.

But this single number tells only part of the story. The sensitivity analysis using a fixed-effect model produced a slightly higher estimate of 33% (95% CI 30–35%). The researchers also found that results varied considerably from study to study — the heterogeneity test was high (I² = 72.7%, p<0.0001), meaning the individual studies genuinely differed from each other in ways beyond random chance.

The prevalence of residual symptoms varied enormously across individual studies. At one extreme, a 1988 study by Pfister and colleagues reported no residual symptoms at all among 21 patients. At the other extreme, a 1989 study by Viader and colleagues found that 8 of 12 patients (67%) continued to have symptoms. The total number of patients contributing to this pooled analysis was 1,469.

## The Case Definition Effect: 24% vs. 31%

The most striking finding — and the one with the greatest implications for interpreting the "post-Lyme syndrome" debate — emerged when the researchers separated studies by case definition.

In studies using the rigorous **"probable/definite" case definition**, involving 547 patients across 11 studies, the mean weighted prevalence of residual symptoms was **24%** (95% CI 16–33%). In studies using the broader **"possible" case definition**, involving 922 patients across 27 studies, the rate was significantly higher at **31%** (95% CI 25–37%). This difference was **statistically significant (p = 0.0048)**, meaning there is less than a 0.5% probability that this difference occurred by chance.

Fixed-effect sensitivity analyses produced similar patterns: 28% (95% CI 24–32%) for the "probable/definite" group and 35% (95% CI 32–39%) for the "possible" group.

The researchers interpreted this finding as evidence that the "possible" case definition is too unspecific. When patients are included in studies based on less rigorous diagnostic criteria, some of them may actually have other conditions that merely resemble Lyme neuroborreliosis. These mislabeled patients would understandably not respond to antibiotic treatment, inflating the apparent rate of "residual symptoms" in those studies.

This is not a trivial methodological nuance. It suggests that some of the highest estimates of chronic symptoms after Lyme disease — the ones fueling patient anxiety and the "chronic Lyme" controversy — may be based on studies that included patients who never actually had Lyme neuroborreliosis in the first place.

## How Study Design Affected the Numbers

The type of study also influenced the results. When the researchers broke down the prevalence by study design, they found:

-
**Randomized controlled trials (RCTs):** 33% residual symptom prevalence (95% CI 23–46%, n = 8 studies)
-
**Cohort studies:** 28% residual symptom prevalence (95% CI 22–36%, n = 16 studies)
-
**Case series:** 25% residual symptom prevalence (95% CI 18–34%, n = 14 studies)

The difference between RCTs and case series was statistically significant (p = 0.01885), while the difference between RCTs and cohort studies did not reach significance (p = 0.086). Fixed-effect analyses showed similar estimates for cohort studies (32%, 95% CI 29–36%) and case series (24%, 95% CI 20–30%), but a notably higher prevalence in RCTs (40%, 95% CI 35–45%).

Why would randomized trials report more residual symptoms? The likely explanation is methodological rigor. RCTs typically use standardized follow-up schedules and systematic assessments of every patient, whereas case series may be less thorough in documenting symptoms. In other words, RCTs are probably capturing a more accurate picture — but their higher rates may also reflect the different patient populations and shorter follow-up periods common in trials.

The researchers also checked whether the publication year of a study made a difference, and found no significant correlation (Pearson's r = 0.3, p = 0.0638). In other words, older studies were not systematically reporting more or fewer residual symptoms than newer ones. Visual inspection of the funnel plot revealed no considerable publication bias, giving confidence that the review is not missing a large body of unpublished negative studies.

## The Spectrum of Symptoms: What Patients Actually Reported

Understanding *which* symptoms persist is just as important as knowing *how many* patients experience them. The spectrum of residual symptoms was reported for 687 patients in studies using the "probable/definite" definition and 624 patients in studies using the "possible" definition (1,311 total). The researchers grouped similar symptoms together for comparison and summarized rarely reported ones — such as encephalopathy, Parkinsonism, central nervous system involvement, hearing loss, impaired vision, bladder disorders, numbness, restless legs, and sleep problems — under the category "diverse."

The following table shows the proportion of patients experiencing each type of residual symptom in all studies combined, and how those proportions differed between the two case definition groups:

Symptom
All Studies (n=1,311)
Probable/Definite (n=687)
Possible (n=624)
Statistical Significance

Pain
10.37%
2.77%
18.75%
p < 0.0001*

Cranial neuropathy (nerve disorders affecting the head/face)
9.84%
3.6%
14.59%
p < 0.0001*

Cognitive disturbances (thinking, memory, concentration)
8.77%
1.6%
16.67%
p < 0.0001*

Diverse (unspecified and rare symptoms)
7.55%
3.64%
12.02%
p < 0.0001*

Sensory disturbances (numbness, tingling, altered sensation)
6.48%
5.24%
7.85%
p = 0.1483

Paresis (muscle weakness or paralysis)
5.57%
2.33%
9.13%
p < 0.0001*

Headache
4.88%
1.75%
8.33%
p < 0.0001*

Neurasthenia/fatigue
2.44%
0%
5.13%
p < 0.0001*

Unsteadiness/ataxia/vertigo (balance and dizziness problems)
2.29%
2.62%
1.92%
p = 0.4329

**Statistically significant at the adjusted threshold of p < 0.0055 (Bonferroni correction applied for multiple comparisons).*

A few things jump out from this data. In the overall picture, **pain** (10.37%), **cranial neuropathy** (9.84%), and **cognitive disturbances** (8.77%) were the most frequently reported residual symptoms. These are meaningful numbers for patients: they show that symptoms do occur, but also that they do not occur in the majority of treated patients.

The differences between the two case definition groups are dramatic. For virtually every symptom — pain, cranial neuropathy, cognitive disturbances, paresis, headache, fatigue, and diverse symptoms — patients in studies using the looser "possible" definition were many times more likely to be counted as having residual symptoms. For all of these, the differences were highly statistically significant (p < 0.0001). Only two categories showed no significant difference: sensory disturbances (p = 0.1483) and balance problems (p = 0.4329).

Perhaps the most striking finding is about fatigue — the symptom most commonly associated with "post-Lyme syndrome." In studies using the rigorous "probable/definite" case definition, there were **zero reports of residual fatigue**. Zero. The 2.44% overall rate of fatigue in all studies was entirely driven by the 5.13% reported in the less rigorous "possible" definition studies.

Only 7 of the included studies assessed how severe the residual symptoms were. Of those, 6 described all residual symptoms as "mild" or "low grade," while just 1 study distinguished between "minor" and "major" residual symptoms, with only the latter having considerable impact on daily life. This suggests that when residual symptoms do occur after verified LNB, they are often not debilitating.

## The "Post-Lyme Syndrome" Controversy

Some researchers have described a "post-treatment Lyme disease syndrome" characterized by debilitating fatigue and cognitive impairment affecting "a considerable proportion of patients." Patient support groups and some clinicians have interpreted these symptoms as evidence of ongoing chronic infection requiring prolonged antibiotic courses.

This systematic review casts serious doubt on that narrative. The researchers' central argument is that reports of a dramatic "post-Lyme syndrome" with high rates of disabling fatigue and cognitive problems may be **an artifact of unspecific case definitions** in individual studies.

Here is the logic: the "possible" case definition is broad and unspecific, often lacking verification of diagnosis through cerebrospinal fluid analysis. Studies using this definition included a much higher proportion of patients with these non-specific symptoms. But when you look at studies that used strict diagnostic confirmation, the number drops significantly, and fatigue disappears entirely from the list of reported residual symptoms.

The implication is that many patients diagnosed with "chronic Lyme" in these studies may never have had Lyme neuroborreliosis at all. They could have had fibromyalgia, chronic fatigue syndrome, or other conditions that coincidentally produced symptoms overlapping with those commonly attributed to "post-Lyme syndrome." Antibiotic treatment would understandably be ineffective for such patients, and they would continue to have symptoms — creating the false impression of a disease-specific "post-Lyme syndrome."

## Clinical Implications: What This Means for Patients

For patients who are about to start or who have completed treatment for Lyme neuroborreliosis, this review provides several reassuring and practical messages.

**First, most patients recover.** Approximately 72–76% of patients with properly confirmed LNB experience complete resolution of symptoms after standard antibiotic treatment. The nervous system heals well in the majority of cases.

**Second, residual symptoms that do occur are often mild.** In 6 of the 7 studies that assessed severity, residual symptoms were described as "mild" or "low grade." Only one study described any symptoms with major impact on daily life.

**Third, future diagnostic accuracy matters.** The striking difference between "possible" and "probable/definite" case definitions has implications for both clinical care and future research. Doctors should ensure that the diagnosis of LNB is confirmed with appropriate laboratory testing, including cerebrospinal fluid analysis when indicated, before attributing persistent symptoms to the disease. This protects patients from unnecessary antibiotic retreatment and from having their real condition (whatever it may be) overlooked.

**Fourth, if you have persistent symptoms after treatment, they deserve attention.** This is not to dismiss patients who continue to feel unwell. Pain, cognitive disturbances, and other symptoms do occur in a minority of patients. But the evidence suggests that clinicians should evaluate these patients carefully for other possible causes, rather than automatically attributing every symptom to "chronic Lyme disease."

**Fifth, the debate about extended antibiotics needs to be revisited.** If many "post-Lyme syndrome" cases are actually misdiagnosed patients with other conditions, then treating them with additional courses of antibiotics is unlikely to help and may cause harm. This review reinforces the position of major infectious disease and neurological societies that prolonged antibiotic therapy for "chronic Lyme" is not supported by evidence.

## Limitations: What This Study Could Not Prove

No study is perfect, and this systematic review has several limitations that should be acknowledged for a balanced understanding.

**Heterogeneity was high.** Even after splitting studies into subgroups by case definition and study design, considerable statistical heterogeneity remained (I² = 72.7% overall, 77.9% for probable/definite, 68.4% for possible). This means the included studies differed in many ways — different antibiotic agents, different treatment durations, different follow-up periods, and different patient populations — and these differences could not be fully explained by the subgroup analyses. The 28% pooled estimate should therefore be understood as an average across diverse studies, not a precise prediction for any individual patient.

**Severity data were limited.** Only 7 of the 44 studies assessed how much residual symptoms affected patients' quality of life. The review could extract prevalence data (whether symptoms existed) and spectrum data (which symptoms occurred), but it could not reliably measure the impact of those symptoms on daily functioning.

**Treatment efficacy was not the objective.** The review included studies reporting on pharmacological treatment, but it did not aim to compare the effectiveness of different antibiotic regimens. Differences in residual symptoms between studies could theoretically be related to the specific drugs used, and this factor was not analyzed.

**Publication bias cannot be fully excluded.** Although the funnel plot showed no considerable asymmetry, the researchers acknowledge that visual inspection of funnel plots for prevalence reviews is not a validated method.

**Natural course studies were excluded.** The review did not include studies that reported only on the natural course of untreated Lyme neuroborreliosis, which could have provided additional context on how symptoms resolve with versus without treatment. It also may have missed studies reporting on residual symptoms without mentioning treatment information, although this seems unlikely given the comprehensive search.

**Case-control evidence was not included.** Some case-control studies comparing LNB patients to healthy controls have investigated long-term outcomes in terms of fatigue and quality of life. These were not part of the pooled analysis, and the review authors note that the results of such studies remain inconclusive — some show no statistically significant differences between patients and controls.

## Recommendations for Patients

Based on the findings of this systematic review, here are some practical takeaways for patients and their families:

1.
**Insist on a rigorous diagnosis.** If you are being treated for Lyme neuroborreliosis or are experiencing symptoms afterward, ask your doctor what diagnostic criteria were used. Confirmation via cerebrospinal fluid analysis (lumbar puncture) is important for distinguishing true LNB from other conditions.
1.
**Know the realistic odds.** After proper antibiotic treatment, roughly 72–76% of patients with confirmed LNB can expect to be free of residual symptoms. For the 24–28% who do have lingering symptoms, those symptoms are frequently mild — but they can include pain, cranial nerve issues, cognitive disturbances, or balance problems.
1.
**Be skeptical of "fatigue-only" post-Lyme claims.** Since no studies using rigorous diagnostic criteria reported residual fatigue, persistent fatigue alone may point toward a different diagnosis — such as fibromyalgia, chronic fatigue syndrome, or another condition — and deserves a thorough medical evaluation rather than automatic antibiotic retreatment.
1.
**Avoid unproven extended antibiotic treatments.** Current evidence supports 14–21 days of standard antibiotic therapy. Prolonged antibiotic courses for "chronic Lyme" are not supported by scientific evidence and carry risks, including antibiotic side effects, allergic reactions, and the potential for antibiotic resistance.
1.
**Report unusual symptoms.** The review provides a useful reference for which residual symptoms are "common" after LNB (pain, cranial neuropathy, cognitive disturbances) and which are "unusual" (fatigue, sleep disorders, restless legs, bladder issues). Unusual symptoms may warrant additional diagnostic evaluation.
1.
**If you have residual symptoms, seek appropriate specialty care.** Neurologists who specialize in infectious or neuro-inflammatory conditions can help evaluate whether your symptoms relate to the previous infection or to another condition, and can guide appropriate management whether that involves symptom-specific treatments, rehabilitation, or reassurance.

## Frequently Asked Questions

### What is Lyme neuroborreliosis and how does it affect the nervous system?

Lyme neuroborreliosis is a tick-borne infection of the nervous system caused by Borrelia burgdorferi bacteria. It commonly causes inflammation of nerve roots (polyradiculoneuritis), meningitis, and sometimes cranial nerve problems. In prolonged cases, it can lead to encephalomyelitis or stroke-like lesions. It occurs in 3–15% of Lyme disease patients.

### After antibiotic treatment, how many patients have lingering symptoms?

Across 44 studies with 1,469 patients, about 28% had some residual symptom after treatment. When the diagnosis was rigorously confirmed using laboratory testing, the rate was 24%. Studies using a looser case definition reported 31%. So roughly one in four patients has lingering symptoms, but most recover completely.

### Which residual symptoms are most common after Lyme neuroborreliosis?

The most frequently reported residual symptoms were pain (10.37%), cranial neuropathy affecting the head or face (9.84%), and cognitive disturbances such as memory or concentration problems (8.77%). Sensory disturbances, muscle weakness, headache, and balance problems were also reported, though less often. Most residual symptoms were described as mild or low grade.

### Is fatigue a common symptom after properly treated Lyme neuroborreliosis?

No. In studies using rigorous diagnostic criteria, there were zero reports of residual fatigue. The overall fatigue rate of 2.44% came entirely from studies using a broader, less specific case definition. Persistent fatigue alone may point to a different condition, such as fibromyalgia or chronic fatigue syndrome, and deserves a thorough evaluation.

### Why do some studies report much higher rates of post-Lyme symptoms?

Studies using a broad 'possible' case definition reported a 31% residual symptom rate, while those requiring laboratory confirmation reported 24%. The looser definition may include patients who never actually had Lyme neuroborreliosis. Their symptoms may come from fibromyalgia or other conditions that do not respond to antibiotics, inflating the apparent rate of post-Lyme syndrome.

### What is the standard antibiotic treatment for Lyme neuroborreliosis?

Standard treatment follows European and American guidelines. Patients receive antibiotics such as ceftriaxone, penicillin, cefotaxime, or doxycycline for 14–21 days. This systematic review does not support prolonged antibiotic courses for 'chronic Lyme,' as they are not backed by evidence and carry risks of side effects, allergic reactions, and antibiotic resistance.

### I still have symptoms after treatment. What should I do?

First, about 72–76% of patients with confirmed Lyme neuroborreliosis recover fully. If you have residual symptoms, they are often mild. But instead of assuming 'chronic Lyme,' seek a careful evaluation for other possible causes. Ask your doctor what diagnostic criteria were used, and report unusual symptoms like fatigue or sleep problems, which may warrant additional testing.

## Source Information

**Original article title:** Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis

**Authors:** R. Dersch, H. Sommer, S. Rauer, and J. J. Meerpohl

**Journal:** Journal of Neurology (JNeurol), Volume 263, pages 17–24 (2016)

**DOI:** 10.1007/s00415-015-7923-0

**Publication dates:** Received August 21, 2015; Revised September 28, 2015; Accepted September 29, 2015; Published online October 12, 2015

**Author affiliations:** Department of Neurology, Medical Center – University of Freiburg, Germany; German Cochrane Centre, Medical Center – University of Freiburg, Germany; Institute of Medical Biometry and Statistics, Medical Center – University of Freiburg, Germany

*This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and should not replace individualized medical advice from a qualified healthcare professional.*


---
Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay.
Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact
Canonical page: https://diagnosticdetectives.com/products/after-lyme-neuroborreliosis-treatment-how-common-are-lingering-symptoms-a-patients-guide-to-a-major-scientific-review